a trial in china with children using nebulised interferon (alphs or beta unknown)17 Apr 2020 02:32
For what it's worth:
Chen C.
Coronavirus Disease-19 Among Children outside Wuhan, China [In-ternet].
Lancet Child and Adolescent medicine;
Available from: https://pa-pers.ssrn.com/sol3/papers.cfm?abstract_id=3546071
A pre-print, the information should be treated with caution until it has un-dergone peer review.
This is a prospective case series of 31 paediatric cas-es of COVID-19 diagnosed at the Shenzen Third Peoples hospital between Jan 16th and Feb 19th 2020.
This made up 7.9% of all cases diagnosed in Shenzen. They were all confirmed by PCR. None had been exposed to the seafood market in WUhan.
The patients received nebulised interferon and, IV ribavirin or oral lopinovir/ritonavir.
The median age was 6.75, with most patients (41.9%) aged 5-9. Followed by 0-4yrs (32.2%) and 10-14yrs (19.4%). 41.9% were male.
Clinical features: 12/31 Children were asymptomatic. Fever was observed in 14/31, Cough in 13/41, Sore throat in 2/31, Rhinorrhoea in 22/31 and diar-rhoea in 2/31.
Median duration of fever was 2 days, with a range of 1–9 days.
Bloods: Lymphopaenia was not observed. Lymphocytosis occurred in 17/31 patients.
CRP was elevated in 4/31 patients.
Radiology: On admission 64.5% of CT were normal, with 25% having unilateral pneumonia and 9.7% having bilateral. During hospitalization one child developed a unilateral pneumonia whose radiography was initially normal.
Outcome: 23 children had been discharged at the time of writing, and the remainder were well and afebrile.
Sign In
Follow the stocks
